Document Detail

Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients.
MedLine Citation:
PMID:  10461479     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: We looked for an association between the MvaI polymorphism, a recently reported polymorphism on the promoter of the Apo-1/Fas gene, and rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients. METHODS: Two cohorts of Caucasian RA patients (total number = 185) and one cohort of SLE patients (n = 103) were studied. The MvaI polymorphism was typed by polymerase chain reaction and followed by MvaI digestion and gel electrophoresis. RESULTS: A skewed distribution of MvaI genotypes was found in the first cohort of RA patients (n = 103) compared to the controls, as a result of increased MvaI*2 and decreased MvaI*1 homozygosity. This skewed distribution of genotypes was also observed in RA patients with either early onset of disease or with systemic involvement or progressive disease (assessed by the presence of erosions). The frequency of the MvaI*2 allele was significantly increased in female patients (P = 0.035), patients with extra-articular involvement (P = 0.04) and patients with early onset (P < 0.01), compared to the normals. To confirm these findings, the MvaI polymorphism was also examined in a second cohort of RA patients (n = 82). The results in this cohort did not replicate the associations shown in the first cohort of RA patients. Part of this inconsistency could be attributed to different populations and different parameters collected and analysed. In SLE patients, frequencies of MvaI alleles were not statistically different to the controls. However, MvaI*2 homozygosity was significantly higher in SLE patients with photosensitivity (P = 0.03) or oral ulcers (P = 0.01) than in SLE patients without these features. CONCLUSION: The role of the Apo-1/Fas gene promoter MvaI polymorphism in RA and SLE is unclear and further substantiation in larger patient samples is needed.
Q R Huang; V Danis; M Lassere; J Edmonds; N Manolios
Related Documents :
8562389 - Response to immunosuppressive therapy and an hla-drb1 allele in patients with aplastic ...
14620159 - Lung involvement in rheumatoid arthritis.
18410349 - The effect of parental consanguinity on the clinical and laboratory findings of rheumat...
7839069 - Defective mitogen-induced cellular cytotoxicity in untreated patients with active rheum...
23812319 - Csf α-synuclein improves diagnostic and prognostic performance of csf tau and aβ in alz...
18484659 - Protein oxidation markers in the serum and synovial fluid of psoriatic arthritis patients.
21063339 - Multiple sclerosis in jordan and iraq. clinical and social overview.
11493209 - Prediction of aspiration in patients with newly diagnosed untreated advanced head and n...
21239749 - Plasma platelet-derived microparticles in patients with connective tissue diseases.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Rheumatology (Oxford, England)     Volume:  38     ISSN:  1462-0324     ISO Abbreviation:  Rheumatology (Oxford)     Publication Date:  1999 Jul 
Date Detail:
Created Date:  1999-09-08     Completed Date:  1999-09-08     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  100883501     Medline TA:  Rheumatology (Oxford)     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  645-51     Citation Subset:  AIM; IM    
Department of Rheumatology, Westmead Hospital, NSW, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amino Acid Sequence
Antigens, CD95 / genetics*
Arthritis, Rheumatoid / genetics*
Cohort Studies
Lupus Erythematosus, Systemic / genetics*
Middle Aged
Molecular Sequence Data
Photosensitivity Disorders / etiology
Polymerase Chain Reaction
Polymorphism, Genetic*
Promoter Regions, Genetic / genetics*
Reg. No./Substance:
0/Antigens, CD95

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression ...
Next Document:  Prediction of maximal back muscle strength from indices of body mass and fat-free body mass.